Abstract

We determined the role of the heterophilic interaction of vβ3 integrin on endothelial cells with CD31 on leukocytes in mediating leukocyte-endothelial cell interactions. Preincubation of interleukin-4 (IL-4)–stimulated human umbilical vein endothelial cells (HUVECs) with anti-CD31 monoclonal antibodies (MoAbs) enhanced eosinophil adhesion to the IL-4–stimulated HUVECs, and the endothelial CD31-induced enhancement of eosinophil adhesion to IL-4–stimulated HUVECs was prevented by anti–vascular cell adhesion molecule-1 (VCAM-1) MoAb and anti–very late activation antigen-4 (VLA-4) MoAb, but not by anti–intercellular adhesion molecule-1 (ICAM-1) MoAb, anti–lymphocyte function-associated antigen-1 (LFA-1) MoAb, anti–P-selectin MoAb, or anti–E-selectin MoAb. CD31 stimulation of HUVECs increased the adhesive function of vβ3 integrin to its ligand RGD peptide, the binding of which reached a maximum at 10 minutes after the stimulation, and the CD31-induced vβ3 integrin activation on HUVECs was inhibited by inhibitors of protein kinase C and phosphatidylinositol 3 kinase (PI3-kinase). Furthermore, anti-vβ3 integrin MoAb and RGD peptide as well as soluble CD31 inhibited endothelial CD31-induced enhancement of eosinophil adhesion to IL-4–stimulated HUVECs. However, anti-vβ3 integrin MoAb had no significant inhibitory effect on the eosinophil adhesion to IL-4–stimulated or unstimulated HUVECs without CD31 stimulation of HUVECs. Finally, CD31 stimulation of eosinophils increased the adhesive function of 4β1 integrin (VLA-4) to its ligand fibronectin and their adhesion to IL-4–stimulated HUVECs in a VLA-4–dependent manner. These results indicate that CD31-mediated inside-out signaling activates vβ3 integrin on endothelial cells, that the heterophilic vβ3 integrin/CD31 interaction induces β1 integrin-mediated adhesion of eosinophils to endothelial cells, and that the heterophilic interaction itself is not significantly involved in firm adhesion of eosinophils to endothelial cells.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.